UK MHRA approves “triple-strength” Wegovy for obesity

UK—The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted approval for Novo Nordisk’s Wegovy (semaglutide) at its maximum 7.2 mg dose for chronic weight management in the United Kingdom.

This decision positions the UK as the first country globally to authorize this higher dosage strength, moving ahead of the US Food and Drug Administration, which continues to review Novo Nordisk’s label expansion application submitted in November 2025.

Adults living with obesity and a body mass index of 30 kg/m² or higher can now access Wegovy at the 7.2 mg dose level.

The treatment requires administration as three consecutive 2.4 mg doses rather than a single injection.

However, the medication remains off-limits for patients with a BMI below this threshold.

Additionally, individuals seeking to use Wegovy specifically for cardiovascular disease risk reduction cannot receive this particular dosage.

The regulatory approval is based on the STEP-UP Phase IIIb trial, registered under the identifier NCT05646706.

This clinical study revealed that the 7.2 mg dose delivers superior weight reduction results compared to the standard 2.4 mg dose while maintaining a comparable safety and tolerability profile.

The trial data convinced regulators that patients could benefit from the higher dose without experiencing significantly different adverse effects.

Despite receiving the MHRA’s regulatory stamp of approval, the 7.2 mg Wegovy dose faces another critical hurdle before reaching widespread availability across the National Health Service.

The National Institute for Health and Care Excellence (NICE) must now conduct its own cost-efficiency review to determine whether the treatment represents good value for the publicly funded healthcare system.

Only after this assessment is completed can the higher dose become routinely available to NHS patients across England.

This UK approval arrives shortly after Novo Nordisk achieved another significant milestone in the United States.

The company recently secured FDA approval for oral Wegovy, making pharmaceutical history as the first manufacturer to bring a GLP-1 receptor agonist pill to market.

During the 2026 J.P. Morgan Healthcare Conference, Novo Nordisk CEO Maziar Mark Doustdar projected that oral GLP-1 receptor agonists could capture more than one-third of the obesity treatment market share by 2030.

The timing of this approval is particularly significant for the UK’s struggling life sciences sector.

The industry has weathered considerable turbulence recently, with pharmaceutical companies expressing growing frustration over disputes surrounding the Voluntary Scheme for Branded Medicines Pricing, Access and Growth repayments.

These tensions have contributed to declining investor confidence in UK life sciences, raising concerns about the nation’s ability to maintain its competitive position within the global pharmaceutical landscape.

In response to mounting industry concerns, the UK government has taken concrete steps to restore pharmaceutical sector confidence.

The 2026 drug rebate rate has been substantially reduced from 22.9% to 14.5%, though experts interviewed by Pharmaceutical Technology previously indicated this change would produce mixed effects on the country’s overall competitiveness.

The MHRA has simultaneously committed to accelerating its drug approval processes as part of the UK government’s ambitious 10-Year Health Plan.

According to the regulatory agency, these streamlined procedures could enable patients in England to access new medicines three to six months earlier than under current timelines.